Nasopharyngeal Carcinoma Clinical Trials

• Age: 18 Years to 65 Years;

• Eastern Cooperative Oncology Group performance status ≤1;

• Patients with newly diagnosed, histologically confirmed nasopharyngeal carcinoma, the pathological type is non-keratinising carcinoma;

• Tumor staged as Stage III (T3N0 Excepted; AJCC 8th);

• Patients' lymph node without adverse features (no central necrosis, no muscle/skin invasion, no lymph node fusion);

• Normal bone marrow function: white blood cell count \> 4×10\^9/L, hemoglobin \> 90g/L, platelet count \> 100×10\^9/L;

• Normal liver and kidney function: total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine transaminase and aspartate transaminase ≤ 2.5 × ULN, alkaline phosphatase ≤ 2.5 × ULN, creatinine clearance rate ≥ 60 ml/min;

• Receive 3 cycles of indction chemotherapy (GP regimen + Camrelizumab);

• Plasma EBV DNA after the second cycle of concurrent chemotherapy: negative;

⁃ Complete remission after 27 fractions of radiotherapy based on the MRI examination of the nasopharynx and neck (According to Response Evaluation Criteria in Solid Tumors 1.1);

⁃ Patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule;

⁃ Subjects with pregnancy ability must agree to use reliable contraceptive measures from screening to 1 year after treatment.